Skip to main content

Table 3 Associations of HER2 and TOP2A with ER, PgR and Ki67 status (assessed by IHC)

From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

 

ER status

 

PgR status

 

Ki67 status

 
 

Negative

Positive

p

Negative

Positive

p

Low

High

p

 

N (%)

N (%)

 

N (%)

N (%)

 

N (%)

N (%)

 

HER2 (CISH)

  

< 0.001

  

0.001

  

0.035

   Non-amplified

47 (61.8)

173 (83.2)

 

63 (65.6)

156 (83.4)

 

42 (89.4)

176 (75.2)

 

   Amplified

29 (38.2)

35 (16.8)

 

33 (34.4)

31 (16.6)

 

5 (10.6)

58 (24.8)

 

HER2 (mRNA)

  

< 0.001

  

< 0.001

  

0.086

   Low (< 75th perc)

38 (55.9)

166 (82.6)

 

53 (59.6)

151 (84.4)

 

40 (87.0)

168 (74.0)

 

   High (≥ 75th perc)

30 (44.1)

35 (17.4)

 

36 (40.4)

28 (15.6)

 

6 (13.0)

59 (26.0)

 

HER2 (IHC)

  

0.003

  

0.002

  

0.016

   0-1+

47 (58.8)

163 (75.5)

 

61 (58.7)

148 (77.5)

 

43 (87.8)

163 (67.4)

 

   2+

9 (11.3)

25 (11.6)

 

15 (14.4)

19 (9.9)

 

3 (6.1)

31 (12.8)

 

   3+

24 (30.0)

28 (13.0)

 

28 (26.9)

24 (12.6)

 

3 (6.1)

48 (19.8)

 

TOP2A (CISH)

  

0.29

  

0.46

  

0.33

   Non-amplified

64 (90.1)

182 (93.8)

 

83 (91.2)

162 (93.6)

 

41 (97.6)

202 (91.8)

 

   Amplified

7 (9.9)

12 (6.2)

 

8 (8.6)

11 (6.4)

 

1 (2.4)

18 (8.2)

 

TOP2A (mRNA)

  

0.99

  

0.20

  

0.003

   Low (< median)

34 (50.0)

100 (49.8)

 

39 (43.8)

94 (52.5)

 

33 (71.7)

107 (47.1)

 

   High (≥ median)

34 (50.0)

101 (50.2)

 

50 (56.2)

85 (47.5)

 

13 (28.3)

120 (52.9)

 

TopoIIa (IHC)

  

0.39

  

0.99

  

< 0.001

   Negative

29 (40.3)

69 (34.5)

 

33 (35.9)

64 (35.8)

 

32 (78.0)

66 (28.8)

 

   Positive

43 (59.7)

131 (65.5)

 

59 (64.1)

115 (64.2)

 

9 (22.0)

163 (71.2)